Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Relling

Showing results (31-40 of 176) with videos related to

Pageof 18
Sort By:
Clinical Pharmacy|January 1, 1987
Intrapatient variation in aminoglycoside disposition in cystic fibrosisJ A Bosso, M V Relling, P L Townsend, et al.
Leukemia|February 13, 2002
Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurineT Dervieux, M Hancock, W Evans, et al.
Clinical Pharmacology and Therapeutics|September 2, 2011
Pharmacogenetics: call to actionM V Relling, H J Guchelaar, D M Roden, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differencesJ A Johnson, V L Herring, M S Wolfe, et al.
Clinical Pharmacology and Therapeutics|November 1, 1994
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatinM V Relling, H L McLeod, L C Bowman, et al.
Leukemia Research|May 1, 1997
Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?W E Evans, M V Relling, J M Boyett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Human cytochrome P450 maximal activities in pediatric versus adult liverJ G Blanco, P L Harrison, W E Evans, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 1996
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humansE G Schuetz, A H Schinkel, M V Relling, et al.
Clinical Pharmacology and Therapeutics|December 1, 1992
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activitiesM V Relling, J S Lin, G D Ayers, et al.
Developmental Pharmacology and Therapeutics|January 1, 1989
Anticancer therapy as a pediatric pharmacodynamic paradigmW E Evans, M V Relling, J H Rodman, et al.
Pageof 18

Showing results (31-40 of 176) with videos related to

Sort By:
Pageof 18
Clinical Pharmacy|January 1, 1987
Intrapatient variation in aminoglycoside disposition in cystic fibrosisJ A Bosso, M V Relling, P L Townsend, et al.
Leukemia|February 13, 2002
Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurineT Dervieux, M Hancock, W Evans, et al.
Clinical Pharmacology and Therapeutics|September 2, 2011
Pharmacogenetics: call to actionM V Relling, H J Guchelaar, D M Roden, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differencesJ A Johnson, V L Herring, M S Wolfe, et al.
Clinical Pharmacology and Therapeutics|November 1, 1994
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatinM V Relling, H L McLeod, L C Bowman, et al.
Leukemia Research|May 1, 1997
Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?W E Evans, M V Relling, J M Boyett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Human cytochrome P450 maximal activities in pediatric versus adult liverJ G Blanco, P L Harrison, W E Evans, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 1996
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humansE G Schuetz, A H Schinkel, M V Relling, et al.
Clinical Pharmacology and Therapeutics|December 1, 1992
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activitiesM V Relling, J S Lin, G D Ayers, et al.
Developmental Pharmacology and Therapeutics|January 1, 1989
Anticancer therapy as a pediatric pharmacodynamic paradigmW E Evans, M V Relling, J H Rodman, et al.
Pageof 18